Notícias

Select Water Solutions isn't the first energy stock on many investors' list. Maybe it ought to be.

Chevron's rising production, strong cash returns and expanding high-margin oil assets are driving renewed investor optimism in 2026.

WES Q1 earnings top estimates as higher natural gas, crude oil and water throughput boosts revenues and cash flow growth.

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Chevron Corporation (NYSE:CVX). “The one thing I would tell you is the last time oil was at these prices, Chevron was dramatically higher, but you do get a 3.8% yield and they have great cash flow. Mike Wirth [CEO of Chevron] is running it, and I'm gonna say, pull the trigger,” he added. Chevron reported mixed first-quarter results on May 1, with earnings reflecting ongoing cost pressures and market headwinds across its operations.

Just five stocks account for 60% of Berkshire's holdings -- that percentage was even higher in the past.

The global economy is burning through its oil and refined products stockpiles.

Chevron (NYSE:CVX) shareholders are set to vote on Proposal 6 at the upcoming annual meeting. The proposal, backed by JLens and the Anti-Defamation League, calls for an independent third-party report on Chevron’s human rights due diligence in the occupied Palestinian territories. Chevron’s Board and leading proxy advisors are urging investors to vote against the measure, citing potential risks for the company’s Eastern Mediterranean assets. For investors, this vote comes at a time when...

With an annual dividend yield of 3.85%, Chevron Corporation (NYSE:CVX) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. Chevron Corporation (NYSE:CVX) manufactures and sells a range of high-quality refined products, including gasoline, diesel, marine and aviation fuels, premium base oil, finished lubricants, and fuel oil additives. On May 4, Barclays analyst Betty […]

Occidental, Chevron, and ExxonMobil are no-brainer buys amid the Iran war.

Be careful what you wish for.

Chevron (NYSE:CVX) has rallied hard off late-2025 lows, riding a sharp move in WTI crude from $60.04/bbl in January to $100.32/bbl by April. After a 39.44% one-year gain, the question is whether the easy money is already made. Our 24/7 Wall St. price target for Chevron is $163.37 over the next 12 months, implying -11.57% downside ... Is Chevron a Safe Bet in the Energy Sector?

YPF Q1 earnings top estimates as stronger crude oil output, lower costs and improved refining performance increase profitability.

An ETF has done something unusual for a leveraged commodity fund. It has actually rewarded holders. ProShares Ultra Bloomberg Crude Oil (NYSEARCA:UCO) is up 130% year to date, the kind of move that pays for past pain in a fund notorious for grinding holders down. With President Trump’s April 7 announcement of a two-week US-Iran ... Up 130% YTD, This ETF Can Double Again as Iran War Has No End in Sight

June WTI futures prices are slowly moving higher, over $99 today. One profitable play is to sell short out-of-the-money one-month Chevron calls and puts. I discussed this last month, and it has worked out.

CVE's Q1 earnings beat estimates as higher oil sands production and stronger refining margins increase profitability.

Chevron’s first quarter results for 2026 were met with a negative market reaction, reflecting investor concerns about flat sales and a notable drop in operating margin, despite meeting Wall Street’s revenue expectations. Management attributed the quarter’s performance to strong upstream production—including a substantial boost from legacy Hess assets integration—and disciplined execution across volatile markets. CEO Michael Wirth highlighted operational resilience and the company’s ability to ca

SUN tops Q1 estimates on higher fuel sales volumes, stronger margins and a $102M boost from inventory accounting gains.

Matador Resources' Q1 earnings top estimates as stronger production volumes offset weak natural gas price realizations and lower revenues.

SHEL's Q1 beat, buybacks and dividend hike highlight strong cash visibility and trading strength amid volatility.

BP (NYSE:BP) just received a rare same-day double upgrade from Wall Street. Argus moved BP stock to Buy from Hold, and RBC Capital lifted the stock to Outperform from Sector Perform with a 700 GBp price target. The simultaneous bullish shift signals coordinated conviction that BP’s recovery story is finally taking shape under new CEO ... BP Just Got a Wall Street Double Upgrade: Argus, RBC Both Turn Bullish on Recovery Story

Geopolitical conditions heavily shape oil prices. When conflict erupts near oil-producing regions, prices spike, and naturally, when peace prevails, they fall. Several key mechanisms explain this relationship. Wars embed a “geopolitical risk premium” into oil prices, reflecting fears of supply disruption. Peace eliminates that premium. Conflicts also trigger sanctions that block oil exports; diplomatic resolutions ... Peace Will Bring Lower Oil: Warren Buffett’s Top Energy Picks for Berkshire Ha

European oil and gas companies that posted huge profits in the first quarter on soaring prices caused by the war in the Middle East face new calls from London to Paris to tax their outsized gains.View on euronews

Shell's CEO is warning that the world has a 1 billion-barrel hole to dig out of, and it could get worse before it gets better.

Recent performance snapshot Chevron (CVX) has pulled back recently, with the stock showing a 1 day return of 1.44% decline, a 7 day return of 5.59% decline, and a month move of 9.45% decline. Over longer periods, Chevron’s total return is 0.91% for the past 3 months, 17.06% year to date, 39.17% over the past year, 32.64% over 3 years, and 110.67% over 5 years. At the last close, the stock traded at US$182.50, giving Chevron an equity market value of about US$366.1b. Reported annual revenue...

Berkshire bought NYT, but strong execution and optionality may not justify today's valuation premium

This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.